Avian Influenza A/H5N1 Vaccine

Technology #2015-151

Several novel naturally processed and HLA presented influenza A/H5N1-derived peptides from a class I HLA-A0201 molecules have been identified. A mass spectrometry approach was used to identify five influenza peptides from a B-cell line (homozygous for HLA-A0201) after infection with influenza A/H5N1 virus. The immunologic relevance and specificity of these identified influenza-derived peptides have been investigated by examining the in vitro IFN-g ELISPOT immune responses in peripheral blood T cells to these peptides in healthy persons (n=13) immunized with influenza A/H5N1 vaccine. PBMCs from vaccinated subjects were responsive to synthetic peptides in vitro. These peptides could be used to develop a peptide-based avian influenza A/H5N1 vaccine.